These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 39281673)

  • 1. Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles.
    Song Z; Tao Y; Liu Y; Li J
    Front Immunol; 2024; 15():1444437. PubMed ID: 39281673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy.
    Ahmadi SE; Soleymani M; Shahriyary F; Amirzargar MR; Ofoghi M; Fattahi MD; Safa M
    Cancer Gene Ther; 2023 Jul; 30(7):936-954. PubMed ID: 36854897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral Vectors, Exosomes, and Vexosomes: Potential armamentarium for delivering CRISPR/Cas to cancer cells.
    Farzanehpour M; Miri A; Alvanegh AG; Gouvarchinghaleh HE
    Biochem Pharmacol; 2023 Jun; 212():115555. PubMed ID: 37075815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment.
    Yan B; Liang Y
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
    Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
    Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
    Wilbie D; Walther J; Mastrobattista E
    Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas gene editing and delivery systems for cancer therapy.
    Li Y; Zhou S; Wu Q; Gong C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1938. PubMed ID: 38456346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer.
    Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C
    Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral Delivery of Compact CRISPR-Cas12f for Gene Editing Applications.
    Sharrar A; Meacham Z; Staples-Ager J; Arake de Tacca L; Rabuka D; Collingwood T; Schelle M
    CRISPR J; 2024 Jun; 7(3):150-155. PubMed ID: 38695159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles.
    Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S
    J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revolutionizing Lung Cancer Treatment: Innovative CRISPR-Cas9 Delivery Strategies.
    Singh D
    AAPS PharmSciTech; 2024 Jun; 25(5):129. PubMed ID: 38844700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral Vector System: A Comprehensive Overview of Constructions, Therapeutic Applications and Host Responses.
    Park A; Lee JY
    J Microbiol; 2024 Jul; 62(7):491-509. PubMed ID: 39037484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.
    Woodward EA; Wang E; Wallis C; Sharma R; Tie AWJ; Murthy N; Blancafort P
    Methods Mol Biol; 2024; 2842():267-287. PubMed ID: 39012601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
    Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
    Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
    Yu W; Wu Z
    Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors.
    Wang D; Zhang F; Gao G
    Cell; 2020 Apr; 181(1):136-150. PubMed ID: 32243786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing.
    Duan L; Ouyang K; Wang J; Xu L; Xu X; Wen C; Xie Y; Liang Y; Xia J
    Chembiochem; 2021 Dec; 22(24):3360-3368. PubMed ID: 34418266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering the Delivery System for CRISPR-Based Genome Editing.
    Glass Z; Lee M; Li Y; Xu Q
    Trends Biotechnol; 2018 Feb; 36(2):173-185. PubMed ID: 29305085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.